Regeneron, Inc. (REGN) long.All description on the chart.
Please, don't forget to like and follow.
Thank you.
Biotechnology
VXRT - Big Moves AheadAll,
This may drop to $2.30-2.50 but after that should be a move up. We are moving into a previous consolidation area. The news etc outlook prior to the virus all look like it should move up. However, you never know so keep an eye out of course. We should see some movement this week for sure.
Trade idea #BTK long on a break of the 5450 levelBiotechnology belongs to the sectors of the stock market which were rather moderately affected by the Coronacrisis. In fact, in the second half of april the NYSE ARCA Biotechnology Index even managed to surpass its pre-corona levels to attack its previous high at about 5.420. However the advance of the preceding days was too strong to get beyond that level and in line with the total market the index got rejeceted at that resistance level.
Looking now at the weekly chart a multi-month range between 3850 and 5450 can be seen which followed a previous advance of the index. Trend trader would now expect the index to pass the upper boundary of that range but we have to patiently wait if that will happen or if the index will continue to trade within that range.
For a long breakout trade the following trading strategies are possible:
a/ set a buy stop order > 5.550 (upper boundary at 5.450 + 2% )
b/ go long on a daily close > 5.450
c/ go long on a weekly close > 5.450 (unless price gets too far away from the 5450 handle)
d/ after a successfull breakout wait for a consolidation back to the 5450 level to look for a Long entry
Which strategy you use depends of course on your trading style. Also a combination of the 4 strategies could make sense, i.e. 33% for a/, 17% for b/, 17% for c/ and 33% for d/.
Stop loss should be the last swing low. If the index won't take out last week's low this would be 4.950, otherwise the stop must be adjusted.
A first target for 50% of the position could be set at the round figure of 7.000.
I will update on the trade idea. See you.
$MYOK can rise in the next daysContextual immersion trading strategy idea.
MyoKardia, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
The share price rose after the company announced that its experimental obstructive hypertrophic cardiomyopathy drug Mavacamten met all of its primary and secondary endpoints in a late-stage trial.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $112,93;
stop-loss — $98,56.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
$BEAM can rise in the next daysContextual immersion trading strategy idea.
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States.
The share price rose after good earnings. I see some preconditions the share price will continue growing.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $21,45;
stop-loss — $19,62.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
$MGNX can rise in the next daysContextual immersion trading strategy idea.
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States.
The share price rose after good earnings. I see some preconditions the share price will continue growing.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $27,29;
stop-loss — $20,01.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
INO going down, major resistanceFib levels are acting as strong support and resistance, is likely to start going down the fib ladder like a basketball.
Also we have a trendline resistance from the last few weeks.
BIOTRON - Primed to MOVE!Watching BIOTRON closely. 2 Scenarios:
1. Break of internal trend within the symmetrical triangle will see us return to the .065-.080 region (AREA OF INTEREST).
-We've had 2 bounces on the .382 Fib region creating a double top @ .115 Equilibrium
-Break of internal uptrend trendline.
-Currently broken the center band of bollinger bands.
-We've also had a death cross on MACD and is starting to spread.
-Waiting on break of support at .088
2. If POSITIVE results are announced shortly for any of BIOTRONS Projects/Programs (Anti Viral Drug Program, HIV Program, HBV Program) We should see a break out of Symmetrical Triangle.
-Break of downtrend possible.
-Retest of .011 Equilibrium VERY possible.
-New Market Structure will form with Higher LOW & Higher HIGH.
-Volume will be brought back into the market.
-My next target would be major resistance at .014
A very interesting company with real world prospects. I have been following them since the earlier in the year, with Phase 2 HIV-1 Clinical Trials being successful, HBV Pre-Clinical Trials and work on Anti Viral Drug Development with a keen interest on Covid-19.
These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!
Arena Pharmaceuticals $ARNA cup w handle$ARNA failed to break the resistance of cup w handle today.
If you find my charts useful, please just leave me a "Like"
thx
Sarepta Therapeutics $SRPT$SPRT is about to break the resistance of cup after a long consolidation. There are two options in front; one ise to break and to continue rising and the other one is forming a handle.
If you find my charts useful, please just leave me a "Like"
thx
IBB - reached forecasted target and should correctIBB reached the target we forecasted on May 6 and at this stage it should have completed primary wave 5. It should now start a correction that can take it to new lows. The alternative scenario would be that we would see a minor correction to around 115 before trend to new highs. However, in both cases prices should follow the path to at least arounf the most probable target of 115. If prices crosses up 136 this analysis should be reviewed. FOLLOW SKYLINEPRO TO GET UPDATES.
Novavax (NVAX): Tell me about my Schiff!I'm bull-ish on Novavax (see Related Idea). I think their approach to the COVID-19 vaccine is promising - their recombinant nanoparticle vaccine technology and Matrix-M adjuvant. They also have positive long-term prospects with their proprietary NanoFlu candidate. This is the big one to me. It's unclear whether COVID-19 becomes seasonal or not but influenza is established and recurring. It fact, it's becoming more difficult to handle with every year. The strains are becoming more advanced and unpredictable. Whether or not Novavax can produce a profitable candidate, I simply don't know. I believe that their patented tech is promising.
Novavax might not produce a COVID vaccine before its competitors (or at all) but they continue to demonstrate their technology and approach works. Example: ir.novavax.com
That being said, tell me about this random Schiff I plotted :)
Matrix-M Adjuvant: novavax.com
NanoFlu Phase 3 topline data: novavax.com
RSV F Vaccine: novavax.com
$ATHX can rise in the next daysContextual immersion trading strategy idea.
Athersys is a biotechnology company, focuses on the research and development activities in the field of regenerative medicine.
The share price rose after good earnings. I see some preconditions the share price will continue growing.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $2,85;
stop-loss — $2,57.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
$NBSE can rise in the next daysContextual immersion trading strategy idea.
NeuBase Therapeutics is a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes.
The demand for shares of the company looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $8,13;
stop-loss — $7,60.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Novavax Big Break Out Day!- $NVAX, +30.80% as it rallied after the biotech announced it received a large $384m investment for its COVID-19 vaccine candidate and beat Earnings expectations.
- Technically we are in a strong uptrend - just broken out of its corrective move down. This is the type of stock which may take off further quite quickly - we could wait for a pullback (possibly at the old highs) or buy this breakout at the open market. Will depend on your risk appetite.
- Targets have been set based on the Pitchforks and Median Line Theory.
Sorrento Therapeutics $SRNEUnconfirmed double bottom for $SRNE. It needs to break $2.66 for target price
If you find my charts useful, please just "Like"
BioCryst Pharmaceuticals $BCRXIt just broke the pivot with heavy volume. RSI is hitting the resistance. It may be back test at $4.35
Golden Goose IPO "PPD" This IPO was just listed on FEB, 6th 2020 and will be killing it every earnings and has the potential to big a really big play in the market during these times. The chart I have posted is a 4HR time frame. Definitely one to add to your portfolio for awhile! I can see this being a GOLDEN GOOSE to get into early during these times! options plays are good on this one as well to play.
Pivot points and resistance are $26.86 / $28 / $29.37 on the 4HR time frame. The Linear reg. channel is bullish on all time frames up to the 3 min. when it becomes semi neutral.
Listed at 100% buy right now on Robinhood
NASDAQ:PPD Inc. provides drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. The firm also provides clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations and other industry participants. Its clinical development services include all phases of development (Phase I-IV), peri- and post-approval and site and patient access services; laboratory services offers advanced testing services, including bioanalytical, biomarker, vaccine, good manufacturing practice and central laboratory services. The company was founded by Fred Eshelma in 1985 and is headquartered in Wilmington, NC.
$IFRX can rise in the next daysContextual immersion trading strategy idea.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the United States and Europe.
The share price rose after good earnings. I see some preconditions the share price will continue growing.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $7,22;
stop-loss — $6,73.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
TG Therapeutics $TGTX is on the top$TGTX is hitting the 5 years high. It did %65 in this week so far. RSI is still 66 on weekly and needs more for breakout. It may pull back before continues
Arrowhead Pharmaceuticals $ARWR $ARWR started to make HH and LH which is a good sign for an uptrend. Next it needs to break $40.19 and make ne HH at $46.58.
OGEN Long into and past earnings! Starting Today!AMEX:OGEN is going to rip into earnings then pull back right before then pop for 100% or more post earnings. Here are my price targets placed for the next week every few days starting with next Monday.
DD:
OGEN has
*1 drug for Oral Mucosis just finished Phase 2 trial, FULL data will be release on earnings call and ironically at the same time they have $15 Million worth of Warrants that will expire the day before. :) Also OGEN as obtained FDA Fast Track approval for this drug and marketing agreements completed in Europe to put it on the shelves immediately if Phase 2 data is good.
*1 drug for lowering cholesterol by 70% currently in Phase 1trial, expect results and Ph2 announcement mid/early summer.
*$21 Million cash on hand with burn rate of less than 10 Million per year.
*This Monday OGEN bought a COVID19 trial drug company with 4,000,000 shares or roughly $1 Million.
Trading in a channel, well established bases in this range over the last year or two, no need for extra funding for at least 1 year.
VBI vaccines $4 EOY Target Successful completion of the pivotal Phase 3 program for Sci-B-Vac®, on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020
Announcement of pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS – human clinical study material expected to be available in Q4 2020
Expanded immunologic, tumor, and clinical data from recurrent GBM Phase 2a clinical study of VBI-1901 expected mid-year and Q4 2020
Human proof-of-concept data from Phase 1b/2a study of hepatitis B immunotherapeutic, VBI-2601, expected H2 2020
Net cash proceeds of approximately $54 million added to balance sheet from underwritten public offering in April 2020
11 Million shares bought by insider www.sec.gov
